Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19. The preliminary findings, published in The Lancet and presented at this year’s European Congress of…
Read More
Turkish official says CoronaVac vaccine 91.25% effective
An experimental COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac is 91.25% effective, a Turkish health official said on Thursday. Dr. Serhat Unal, an infectious disease expert serving on Turkey’s medical board, said the finding is based on early results…
Read More